Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 28, 2003

View Archived Issues

NCI to evaluate TNFerade for rectal cancer

TaiGen receives funding for SARS drug development efforts

Anti-TNF-alpha antisense oligonucleotide effective and safe in rheumatoid arthritis

Polyphenon E (EGCg) improves preaged and damaged facial skin

Alefacept therapy beneficial in the treatment of psoriasis

CTLA-4Ig reported to improve quality of life and physical function in rheumatoid arthritis

Statins in the prevention of atherosclerosis caused by SLE

Novel Kv1.3 channel blockers with utility in multiple sclerosis and other immune disorders

Nonpeptide GnRH antagonists and their use claimed by Ferring

Novel elastase inhibitors prepared and tested by Dainippon scientists

Meiji Milk and Kitasato Institute researchers discover new agents for flu

Meiji Milk patent describes a cholesterol-lowering peptide

Two series of MEK inhibitors identified at Array BioPharma

New antifungal agents, their isolation and biological evaluation claimed by Sankyo

Kyowa Hakko presents urethra-selective agents for urinary incontinence therapy

Safety and pharmacokinetics of single-dose MEDI-522 in rheumatoid arthritis

LibiGel meets endpoints in interim analysis of phase II trial for FSD

Aventis submits complete response for Ketek

Shareholder approval for Cell Therapeutics/Novuspharma merger

FDA schedules advisory committee review date for Ranexa

IBC enters research collaboration with Schering for cancer

Stalevo approved for Parkinson's disease in E.U.

Teva to commercialize OrCel in Israel

Studies support antiinflammatory, osteogenic and muscle-healing properties of BPC-157

OSI-7904L evaluated in new phase II study for gastric cancer

TA-CD advances into phase IIb for cocaine addiction

Antitumor agent CCI-779 as potential therapy for RA patients

Preclinical efficacy, safety and PK data discussed for IDN-6556 at AASLD meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...